美国Pacira  
是专注于临床和商业发展的新产品，满足急性保健医生和病人的需求一个新兴的专业制药公司。该公司目前的重点是术后疼痛控制的非阿片类产品的发展，商业EXPAREL®（布比卡因注射脂质体悬浮液），其主导产品，在2012年4月在美国推出。 EXPAREL和两个其他市售产品利用Pacira专有产品交货技术DepoFoam®封装在不改变其分子结构的药物，然后释放超过所需的时间内，一个独特的平台。

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients.

A Focus on Pain Management

Our primary focus lies in the development of non-opioid products for postsurgical pain control. We believe we have the technology to improve products' efficacy and safety and make a critical difference to patients in terms of dosing frequency and administration.

Now Available: EXPAREL® (bupivacaine liposome injectable suspension) is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL combines bupivacaine with the DepoFoam® drug delivery platform to provide postsurgical pain control with a single intraoperative infiltration.
Our proven product delivery technology, DepoFoam, is a multivesicular liposome technology that encapsulates drugs without altering their molecular structure and then releases them over a desired time period (from 1 to 30 days); it has been used to reduce the dosing frequency and extend the duration of action of DepoCyt(e)® and DepoDur® for over a decade.